<SEC-DOCUMENT>0001969223-25-000676.txt : 20250827
<SEC-HEADER>0001969223-25-000676.hdr.sgml : 20250827
<ACCEPTANCE-DATETIME>20250827172811
ACCESSION NUMBER:		0001969223-25-000676
CONFORMED SUBMISSION TYPE:	144
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250827
DATE AS OF CHANGE:		20250827

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Apellis Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001492422
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				271537290
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		144
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	001-38276
		FILM NUMBER:		251266568

	BUSINESS ADDRESS:	
		STREET 1:		100 FIFTH AVENUE
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
		BUSINESS PHONE:		617-977-5700

	MAIL ADDRESS:	
		STREET 1:		100 FIFTH AVENUE
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451

REPORTING-OWNER:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Francois Cedric
		CENTRAL INDEX KEY:			0001658080
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		144

	MAIL ADDRESS:	
		STREET 1:		6400 WESTWIND WAY
		STREET 2:		SUITE A
		CITY:			CRESTWOOD
		STATE:			KY
		ZIP:			40014
</SEC-HEADER>
<DOCUMENT>
<TYPE>144
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>144</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001658080</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <issuerInfo>
      <issuerCik>0001492422</issuerCik>
      <issuerName>Apellis Pharmaceuticals, Inc</issuerName>
      <secFileNumber>001-38276</secFileNumber>
      <issuerAddress>
        <com:street1>100 5th Ave </com:street1>
        <com:city>Waltham</com:city>
        <com:stateOrCountry>MA</com:stateOrCountry>
        <com:zipCode>02451</com:zipCode>
      </issuerAddress>
      <issuerContactPhone>6154301983</issuerContactPhone>
      <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>The Cedric Francois Irrevocable Trust of 2023 - 2 DTD 4/6/2023</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
      <relationshipsToIssuer>
        <relationshipToIssuer>Officer</relationshipToIssuer>
      </relationshipsToIssuer>
    </issuerInfo>
    <securitiesInformation>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <brokerOrMarketmakerDetails>
        <name>UBS Financial Services Inc</name>
        <address>
          <com:street1>1000 Harbor Blvd</com:street1>
          <com:street2>3rd Floor</com:street2>
          <com:city>Weehawken</com:city>
          <com:stateOrCountry>NJ</com:stateOrCountry>
          <com:zipCode>07086</com:zipCode>
        </address>
      </brokerOrMarketmakerDetails>
      <noOfUnitsSold>225000</noOfUnitsSold>
      <aggregateMarketValue>6462500</aggregateMarketValue>
      <noOfUnitsOutstanding>125453000</noOfUnitsOutstanding>
      <approxSaleDate>08/27/2025</approxSaleDate>
      <securitiesExchangeName>NASDAQ</securitiesExchangeName>
    </securitiesInformation>
    <securitiesToBeSold>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <acquiredDate>02/27/2023</acquiredDate>
      <natureOfAcquisitionTransaction>Option Exercise</natureOfAcquisitionTransaction>
      <nameOfPersonfromWhomAcquired>Cedric Francois</nameOfPersonfromWhomAcquired>
      <isGiftTransaction>N</isGiftTransaction>
      <amountOfSecuritiesAcquired>160037</amountOfSecuritiesAcquired>
      <paymentDate>02/27/2023</paymentDate>
      <natureOfPayment>Cash</natureOfPayment>
    </securitiesToBeSold>
    <securitiesToBeSold>
      <securitiesClassTitle>Commons Stock</securitiesClassTitle>
      <acquiredDate>09/01/2023</acquiredDate>
      <natureOfAcquisitionTransaction>Option Exercise</natureOfAcquisitionTransaction>
      <nameOfPersonfromWhomAcquired>Cedric Francois</nameOfPersonfromWhomAcquired>
      <isGiftTransaction>N</isGiftTransaction>
      <amountOfSecuritiesAcquired>74963</amountOfSecuritiesAcquired>
      <paymentDate>09/01/2023</paymentDate>
      <natureOfPayment>Cash</natureOfPayment>
    </securitiesToBeSold>
    <nothingToReportFlagOnSecuritiesSoldInPast3Months>N</nothingToReportFlagOnSecuritiesSoldInPast3Months>
    <securitiesSoldInPast3Months>
      <sellerDetails>
        <name>Cedric Francois</name>
        <address>
          <com:street1>1212 Castlewood Avenue</com:street1>
          <com:city>Louisville</com:city>
          <com:stateOrCountry>KY</com:stateOrCountry>
          <com:zipCode>40204</com:zipCode>
        </address>
      </sellerDetails>
      <securitiesClassTitle>Common stock</securitiesClassTitle>
      <saleDate>07/17/2025</saleDate>
      <amountOfSecuritiesSold>159090</amountOfSecuritiesSold>
      <grossProceeds>2540000</grossProceeds>
    </securitiesSoldInPast3Months>
    <remarks>Selling shareholder is an irrevocable trust. Cedric Francois, who is the Chief Executive Officer of Apellis Pharmaceuticals, Inc. is the grantor of this trust.</remarks>
    <noticeSignature>
      <noticeDate>08/27/2025</noticeDate>
      <signature>/s/JOSEPH  CASSIDY, for UBS Financial Services Inc, as attorney-in-fact for The Cedric Francois Irrevocable Trust of 2023 - 2 DTD 4/6/2023</signature>
    </noticeSignature>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
